Ferring B.v.

Sudarkodi Alagarsamy

Claudio Daniel Schteingart

Kazimierz Wisniewski

Guangcheng Jiang

Javier Sueiras-Diaz

Pierre Riviere

Robert Felix Galyean

Pascal Danglas

Michael Reidy

Paul Korner

Kazimierz A Wisniewski

This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.

Method of treating prader-willi syndrome

The present invention relates to oxytocin receptor agonist compounds, pharmaceutical compositions comprising the same, use of such compounds for the manufacture of a medicament for treatment of inter alia, abdominal pain, irritable bowel syndrome (IBS), autism, erectile dysfunction, female sexual dysfunction, labor induction and maintenance, lactation induction and maintenance, postpartum hemorrhage, Post Traumatic Stress Disorder (PTSD), pain, anxiety and other conditions, as well as to methods for the treatment of such conditions, wherein such compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification: 

Oxytocin receptor agonists

Novel GLP-2 analogs with improved pharmacokinetic properties are described as well as their use in the treatment of disease.

Peptidic GLP-2 agonists

Growing community of inventors

San Diego, CA, United States of America

Sudarkodi Alagarsamy